In the war against two of the world's most pressing health challenges - obesity and type-2 diabetes - a major new offensive has been opened by the discovery of a new generation of weight-loss drugs.
Of these new pharmaceutical interventions Ozempic, the brand name of manufacturer Novo Nordisk’s semaglutide formulation, has attracted the most interest…
